Inclusion Criteria:  Participants must be ≥ 12 years of age inclusive, at the time of signing the informed consent/assent. Previously treated patients (≥ 150 EDs) with congenital hemophilia A. Prophylaxis with any SHL FVIII product with a stable dose/regimen for at least 12 months (including at the time of screening) before entering the study and documented in medical records. Documented bleeding rate (ABR) for at least the 6 months prior to study entry. No history or current evidence (≥ 0.6 BU/mL) of FVIII inhibitors. If they are human immunodeficiency virus (HIV) positive, cluster of differentiation 4 (CD4) + lymphocyte count should be > 200/mm^3 within 1 year before entering the study and documented in medical records. Participants who are willing to complete an electronic diary (eDiary). Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. For adolescent participants (≥ 12 to < 18 years), a legal guardian must be available to help the study-site personnel ensure follow-up; accompany the participant to the study site on each assessment day according to the SoA (e.g. able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures); consistently and consecutively be available to provide information on the participant using the PROs during the scheduled study visits; accurately and reliably dispense study intervention as directed. For adolescent participants, a legal guardian must be able to accurately maintain the child's take-home record, including items of general health.  Exclusion Criteria:  Any other inherited or acquired bleeding disorder in addition to hemophilia A. Platelet count < 100,000/mm^3 The participant is currently participating in another investigational drug study or has participated in a clinical study involving an investigational drug or device within 30 days of signing informed consent. The participant has a planned major surgery.  Documentation of missing risk score parameters  . - Known hypersensitivity to the drug substance, excipients, or mouse or hamster protein.  Any other significant medical condition that the investigator feels would be a risk to the participant or would impede the study. Close affiliation with the investigational site; e.g. a close relative of the investigator, dependent person (e.g. employee or student of the investigational site). Otherwise vulnerable participants (e.g. participants who are in custody by order of an authority). Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures (i.e. eDiary completion), restrictions, and requirements.